The development of bulk drugs market

New chemical body (NCEs) and more complex structure, promote technological progress and market development. Drug classification tend to be more precise result derived many of the emerging pharmaceutical market, but also to meet the treatment needs of the past can not be met. Traditional chemical to be support for the development of emerging biotechnology, thereby allowing more and more cutting-edge innovation in the field of drug discovery research.Biotechnology as an emerging field, and its products in the market has a bright future. Over the past 10 years, biotechnology-based drugs to obtain a number of leading dynamic sales growth. The most popular are (promoting) erythropoietin, its sales from $ 500 million in 1988 increased to $ 3,000,000,000 in 1998. Recombinant insulin products and cerebrospinal fluid (CSF) products have similar growth. Looking ahead, as the world's population is aging, some diseases affecting the elderly such as Alzheimer's disease and Parkinson's disease will increase, and therefore the treatment of age-related diseases, Resveratrol drug sales has also grown. Other rapid growth is always a serious lack of areas, including treatment and prevention of HIV / AIDS drugs (particularly in developing countries even scarcer), and a gradual increase of bacterial resistance due to need of new antibiotics. Oncology, metabolic diseases, central nervous system diseases and mental illness or depression is also high demand for new areas of the body chemistry. In addition, help to improve the quality of life of drugs and medicines for disease prevention and the development of NCEs and APIs to create an important opportunity. In the future, no longer a simple treatment of disease, but how to enhance the quality of life and improve health. The most convincing in this regard is Pfizer's erectile dysfunction Viagra, listed on the first month to the end of the year sales were $ 608 million is reached in April 1998. Pharmaceutical industry in developing innovative medicines to market and the variety and quantity of the considerable progress to advanced intermediates and APIs to increase development opportunities. Changes in drug formulations to promote chemical manufacturers to re-evaluate their marketing efforts. Focus on the past, large quantities of raw tonnage level drug sales, is now expanding the business needs of small quantities of very great importance. Consumption also contributed to growth of APIs. It has entered clinical use, such as Prilosec, Irinotecan Prozac and Lipitor have great market demand. APIs in the best-selling, Astra Pharmaceuticals Prilosec for two consecutive years ranked first in sales in the United States in 1998 to $ 2.8 billion, as of July 1999 has been $ 2 billion in sales. Source:http://www.cospcn.com